CONTEXT: Overt thyroid disease is associated with profound adverse health outcomes; however, data are conflicting for studies of borderline/subclinical thyroid dysfunction. Many studies of subclinical thyroid disease have had low power and were prone to selection bias. In contrast, large datasets are available from community studies in healthy individuals. Studies of the effects of variation of thyroid function across the reference range on health outcomes in these populations may provide useful information regarding thresholds for treatment of abnormal thyroid function. EVIDENCE ACQUISITION: MEDLINE and the Cochrane Database of Systematic Reviews and Controlled Trials Register were searched for articles studying the effect of variation in thyroid hormone parameters within the reference range on cardiovascular, bone, metabolic, pregnancy, neurological, and psychological outcomes. EVIDENCE SYNTHESIS: Higher TSH/lower thyroid hormone levels are associated with more cardiovascular risk factors and cardiovascular events and worse metabolic parameters and pregnancy outcomes, whereas lower TSH/higher thyroid hormone levels are associated with reduced bone mineral density and increased fracture risk. The evidence base was good for cardiovascular, metabolic, bone, and pregnancy outcomes; however, high-quality data remained lacking for neurological and psychological outcomes. CONCLUSIONS: Common variation in persons with thyroid function in the normal range are associated with adverse health outcomes. These data suggest, by extrapolation, that carefully monitored treatment of even modest elevations of TSH may have substantial health benefits. Appropriately powered large-scale clinical trials analyzing the risks vs benefits of treating subclinical thyroid disease are required to determine whether these benefits can be achieved with levothyroxine therapy.
CONTEXT: Overt thyroid disease is associated with profound adverse health outcomes; however, data are conflicting for studies of borderline/subclinical thyroid dysfunction. Many studies of subclinical thyroid disease have had low power and were prone to selection bias. In contrast, large datasets are available from community studies in healthy individuals. Studies of the effects of variation of thyroid function across the reference range on health outcomes in these populations may provide useful information regarding thresholds for treatment of abnormal thyroid function. EVIDENCE ACQUISITION: MEDLINE and the Cochrane Database of Systematic Reviews and Controlled Trials Register were searched for articles studying the effect of variation in thyroid hormone parameters within the reference range on cardiovascular, bone, metabolic, pregnancy, neurological, and psychological outcomes. EVIDENCE SYNTHESIS: Higher TSH/lower thyroid hormone levels are associated with more cardiovascular risk factors and cardiovascular events and worse metabolic parameters and pregnancy outcomes, whereas lower TSH/higher thyroid hormone levels are associated with reduced bone mineral density and increased fracture risk. The evidence base was good for cardiovascular, metabolic, bone, and pregnancy outcomes; however, high-quality data remained lacking for neurological and psychological outcomes. CONCLUSIONS: Common variation in persons with thyroid function in the normal range are associated with adverse health outcomes. These data suggest, by extrapolation, that carefully monitored treatment of even modest elevations of TSH may have substantial health benefits. Appropriately powered large-scale clinical trials analyzing the risks vs benefits of treating subclinical thyroid disease are required to determine whether these benefits can be achieved with levothyroxine therapy.
Authors: Jennifer S Mammen; John McGready; Rachael Oxman; Chee W Chia; Paul W Ladenson; Eleanor M Simonsick Journal: Thyroid Date: 2015-08-13 Impact factor: 6.568
Authors: David J Stott; Douglas C Bauer; Ian Ford; Patricia Kearney; Jacobijn Gussekloo; Terence J Quinn; Nicolas Rodondi; Jan Smit; Rudi Westerdorp Journal: Eur Thyroid J Date: 2014-06-11
Authors: Mary H Samuels; Rajani Kaimal; Avantika Waring; Howard A Fink; Kristine Yaffe; Andrew R Hoffman; Eric Orwoll; Douglas Bauer Journal: Thyroid Date: 2016-09 Impact factor: 6.568
Authors: Angela R Buckalew; Jun Wang; Ashley S Murr; Chad Deisenroth; Wendy M Stewart; Tammy E Stoker; Susan C Laws Journal: Arch Toxicol Date: 2020-02-17 Impact factor: 5.153
Authors: Donghee Kim; Eric R Yoo; Andrew A Li; Christopher T Fernandes; Sean P Tighe; George Cholankeril; Bilal Hameed; Aijaz Ahmed Journal: Clin Gastroenterol Hepatol Date: 2018-11-17 Impact factor: 11.382
Authors: Layal Chaker; Christine Baumgartner; Wendy P J den Elzen; Tinh-Hai Collet; M Arfan Ikram; Manuel R Blum; Abbas Dehghan; Christiane Drechsler; Robert N Luben; Marileen L P Portegies; Giorgio Iervasi; Marco Medici; David J Stott; Robin P Dullaart; Ian Ford; Alexandra Bremner; Anne B Newman; Christoph Wanner; José A Sgarbi; Marcus Dörr; W T Longstreth; Bruce M Psaty; Luigi Ferrucci; Rui M B Maciel; Rudi G Westendorp; J Wouter Jukema; Graziano Ceresini; Misa Imaizumi; Albert Hofman; Stephan J L Bakker; Jayne A Franklyn; Kay-Tee Khaw; Douglas C Bauer; John P Walsh; Salman Razvi; Jacobijn Gussekloo; Henry Völzke; Oscar H Franco; Anne R Cappola; Nicolas Rodondi; Robin P Peeters Journal: J Clin Endocrinol Metab Date: 2016-09-07 Impact factor: 5.958